Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JK 07

Next Previous
Drug Profile

JK 07

Alternative Names: JK-07; SAL-007

Latest Information Update: 04 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SalubrisBio
  • Class Heart failure therapies; Monoclonal antibodies; Neuregulins; Peptides; Recombinant fusion proteins
  • Mechanism of Action ERBB 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Heart failure
  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 28 Oct 2025 Salubris Biotherapeutics plans a phase II RENEU-PH trial for Heart failure and Pulmonary hypertension (IV, Infusion) in November 2025 (NCT07221513)
  • 22 Jan 2025 Interim efficacy and adverse event data from the phase IIb RENEU-HF trial in Heart failure released by Salubris Biotherapeutics
  • 24 Apr 2024 JK 07 is still in phase I development in Heart-failure (In the elderly, In adults) in USA (IV, Infusion) (NCT04210375)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top